Zhou Ziyuan, Yuan Yaxia, Zhou Shuo, Ding Kai, Zheng Fang, Zhan Chang-Guo
Molecular Modeling and Biopharmaceutical Center, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536, United States; Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536, United States.
Molecular Modeling and Biopharmaceutical Center, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536, United States; Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536, United States; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536, United States.
Bioorg Med Chem Lett. 2017 Aug 15;27(16):3739-3743. doi: 10.1016/j.bmcl.2017.06.075. Epub 2017 Jun 29.
Human mPGES-1 is recognized as a promising target for next generation of anti-inflammatory drugs. Although various mPGES-1 inhibitors have been reported in literature, few have entered clinical trials and none has been proven clinically useful so far. It is highly desired for developing the next generation of therapeutics for inflammation-related diseases to design and discover novel inhibitors of mPGES-1 with new scaffolds. Here, we report the identification of a series of new, potent and selective inhibitors of human mPGES-1 with diverse scaffolds through combined computational and experimental studies. The computationally modeled binding structures of these new inhibitors of mPGES-1 provide some interesting clues for rational design of modified structures of the inhibitors to more favorably bind with mPGES-1.
人源微粒体前列腺素E合酶-1(mPGES-1)被认为是下一代抗炎药物的一个有前景的靶点。尽管文献中已报道了多种mPGES-1抑制剂,但进入临床试验的很少,且迄今为止尚无一种被证明在临床上有用。为开发用于炎症相关疾病的下一代治疗药物,迫切需要设计和发现具有新骨架的新型mPGES-1抑制剂。在此,我们通过计算和实验相结合的研究报告了一系列具有不同骨架的新型、强效且选择性的人源mPGES-1抑制剂的鉴定。这些新型mPGES-1抑制剂的计算模拟结合结构为合理设计抑制剂的修饰结构以更有利地与mPGES-1结合提供了一些有趣的线索。